论文部分内容阅读
目的:观察NP方案治疗NSCLC的临床疗效,探讨治疗晚期NSCLC有效的化疗方案。方法:入选103例晚期NSCLC患者,随机分为观察组(NP方案)50例及对照组(CAP方案)53例,均完成3个周期化疗,对照观察两组的近期疗效及毒副反应。结果:总有效率观察组为52.0 %,对照组为32.1 %,P<0.05。两组均有消化道反应、骨髓毒性、脱发及局部静脉炎等毒副反应,其中治疗组静脉炎发生率较高。结论:NP方案治疗晚期NSCLC明显优于传统方案CAP,可用作晚期NSCLC一线化疗方案。
Objective: To observe the clinical efficacy of NP regimen in the treatment of NSCLC and to explore the effective chemotherapy regimen in the treatment of advanced NSCLC. Methods: A total of 103 patients with advanced NSCLC were enrolled and randomly divided into observation group (n = 50) and control group (n = 53). All of them completed 3 cycles of chemotherapy, and the short-term efficacy and side effects of the two groups were observed. Results: The total effective rate was 52.0% in observation group and 32.1% in control group, P <0.05. Both groups had gastrointestinal reactions, bone marrow toxicity, hair loss and local phlebitis and other side effects, including the treatment group phlebitis a higher incidence. Conclusion: The NP regimen is superior to the traditional regimen CAP in the treatment of advanced NSCLC and can be used as a first-line regimen for advanced NSCLC.